Total Utang marang Modal: Silexion (SLXN)

Silexion Therapeutics Corp (SLXN) is developing advanced RNA interference methods to combat solid tumors, which will provide the company with immense market control in the future due to its unique method of blocking cell division during KRAS mutations. The market trend for the total debt-to-equity ratio is 36.04. The business currently relies on external investments and test results, as consistent profit is not yet present.

This ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the overall solvency of the issuer. Analyzing the leverage ratio—the relationship of total debt to equity—allows for tracking the dynamics of the debt load between reports, which is critical for Silexion Therapeutics Corp (SLXN) when financing costly developments of drugs against KRAS gene mutations in oncology.